This issue of AVAC’s quarterly newsletter, Px Wire, is now available. Check it out for a deep dive into the data that suggest men who have sex with men may be able protected by oral PrEP, even if they don’t dose every day—and for the reasons why these data do not apply to women. You’ll also find out why messages about global AIDS are on our mind—and what we’d change about the current global conversation.
Px Wire July-September 2017, Vol. 10, No. 3
HIV Prevention Research & Development Investments, 2000–2016: Investment priorities to fund innovation in a challenging global health landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2016, funding for HIV prevention R&D decreased by US$35 million from the previous year to a total of US$1.17 billion. This marks the lowest recorded annual investment in more than a decade. While investments toward research in preventive vaccines, PrEP and medical male circumcision increased in 2016, funding for microbicides, treatment as prevention, female condoms and prevention of vertical transmission decreased.
Global Investment in HIV Cure Research and Development in 2016: Funding for a cure remains a priority
Don’t miss this report looking at investment in cure research in 2016. It’s part of the annual report on investment in research and development that AVAC produces as a member of the Resource Tracking for HIV Prevention Research & Development Working Group.
Advocacy in Uncertain Times: A call to action
AVAC’s report for HIV Vaccine Awareness Day on the state of the HIV vaccine research and development field, including key priorities for advancing research and sustaining support.
Px Wire April-June 2017, Vol. 10, No. 2
This issue of Px Wire, AVAC’s quarterly update on HIV prevention research, offers an advocate’s guide to some new types of biomedical prevention trial designs. You’ll find a summary of long-acting PrEP trials, a lexicon of key terms for the “post-placebo era”, and a handy illustration for looking smart while you explain “double-dummy double-blind”.
What Is Up With DMPA And “Grades” For Family Planning?
AVAC’s sheet on the hormonal contraceptive known as Depo-Provera (DMPA) and the WHO grading system for contraceptives explains key issues in plain language. Research findings have raised questions about the safety and effectiveness of DMPA for women who face a high risk of HIV. WHO evaluates the safety and efficacy of contraceptive methods.
Global Investments in Multipurpose Prevention Technology Research and Development
CAMI Health and the Resource Tracking for HIV Prevention Research and Development Working Group published this 2016 analysis of investment through grants in multipurpose prevention technology. Read on for statistics showing increased funding overall, and review research and development progress to date.
Px Wire January-March 2017, Vol. 10, No. 1
This issue of Px Wire, AVAC’s quarterly update on HIV prevention research, looks ahead at a host of issues we are watching in 2017. Are we confronting “Fast Track” goals with the sober analysis they demand? Will oral PrEP guidelines translate into programs and will programs meet people’s needs? What progress can we expect from studies on the dapivirine vaginal ring, various vaccine candidates or on broadly neutralizing antibodies, which are garnering so much press attention of late? Will global leaders embrace policies that ensure data gaps on key populations will finally be filled?
End-User Research Landscape Mapping & Findings
The HIV Prevention Market Manager undertook an effort to map the landscape of ongoing and planned work on HIV prevention and adolescent girls and young women and other populations in sub-Saharan Africa. This document provides a summary and analysis of the end-user projects and studies underway in order to inform collaborations and identify gaps and next steps in research.
AVAC Introduction to Long-Acting Injectables
A strategy that uses long-acting injectables is being tested now for treatment and prevention. Injected antiretrovirals that are being developed to remain effective for weeks or months could potentially simplify adherence. Our infographic explains the research underway and reviews some of the major questions that research must address.